deCODE Genetics (DCGN) Tops Street's Q2 Estimates
More News related to DCGN
- Semi-Annual Changes to the NASDAQ Biotechnology Index
- Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy
- deCODE Study Expands Clinical Utility of deCODE AF(TM) for Improving the Diagnosis of Atrial Fibrillation and Preventing Stroke
- deCODE genetics (DCGN) Misses Q3 EPS by 2c
- deCODE genetics Announces Third Quarter 2008 Financial Results
More News related to Earnings
- Ahlens, C&A, Creata, Marks & Spencer, Otto International, Pacific Brands and Redcats sign up for China Sourcing Fairs: Fashion Accessories and Baby & Children's Products
- CFIA/Warning: Health Hazard Alert-Santa Lucia Brand Ricotta Cheese May Contain Listeria monocytogenes
- Knight Appoints Kyle W. Stewart Head of Institutional Asian Equities
- One Year Milestone for Air China and the Star Alliance
- Market Resolve Appoints Elizabeth Burns Executive Director of Relationship Management
deCODE genetics (Nasdaq: DCGN) reports a Q2 loss of $0.30, 6 cents better than the analyst estimate of ($0.36). Revenues for the quarter were $15 million, versus the consensus of $12.17 million.
Related Categories
EarningsStocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
